血管紧张素受体-中性内肽酶抑制剂在糖尿病并发症中的作用。
Role of angiotensin receptor-neprilysin inhibitor in diabetic complications.
作者信息
Liu Ying, Lu Cun-Yu, Zheng Yi, Zhang Yu-Min, Qian Ling-Ling, Li Ku-Lin, Tse Gary, Wang Ru-Xing, Liu Tong
机构信息
Department of Cardiology, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China.
Department of Cardiology, Xuzhou No. 1 Peoples Hospital, Xuzhou 221005, Jiangsu Province, China.
出版信息
World J Diabetes. 2024 May 15;15(5):867-875. doi: 10.4239/wjd.v15.i5.867.
Diabetes mellitus is a prevalent disorder with multi-system manifestations, causing a significant burden in terms of disability and deaths globally. Angio-tensin receptor-neprilysin inhibitor (ARNI) belongs to a class of medications for treating heart failure, with the benefits of reducing hospitalization rates and mortality. This review mainly focuses on the clinical and basic investigations related to ARNI and diabetic complications, discussing possible physiological and molecular mechanisms, with insights for future applications.
糖尿病是一种具有多系统表现的常见疾病，在全球范围内造成了巨大的残疾和死亡负担。血管紧张素受体脑啡肽酶抑制剂（ARNI）属于一类用于治疗心力衰竭的药物，具有降低住院率和死亡率的益处。本综述主要关注与ARNI和糖尿病并发症相关的临床和基础研究，探讨可能的生理和分子机制，并对未来应用提出见解。
Zotero 插件